Collegium Pharmaceutical, Inc.
General ticker "COLL" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.0B (TTM average)
Collegium Pharmaceutical, Inc. follows the US Stock Market performance with the rate: 49.9%.
Estimated limits based on current volatility of 1.3%: low 46.94$, high 48.18$
Factors to consider:
- Total employees count: 357 as of 2024
- Top business risk factors: Dependence on successful product commercialization, Liquidity and credit risks, Operational and conduct risks, Product commercialization failure, Supply chain disruptions
- Current price 27.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [23.00$, 37.09$]
- 2025-12-31 to 2026-12-31 estimated range: [22.52$, 36.51$]
Financial Metrics affecting the COLL estimates:
- Positive: with PPE of 4.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 26.91 > 18.64
- Positive: Operating cash flow per share per price, % of 21.63 > 13.24
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 13.76 <= 18.93
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.99
Short-term COLL quotes
Long-term COLL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $463.93MM | $566.77MM | $631.45MM |
| Operating Expenses | $430.61MM | $399.81MM | $461.55MM |
| Operating Income | $33.32MM | $166.96MM | $169.90MM |
| Non-Operating Income | $-62.17MM | $-91.23MM | $-71.33MM |
| Interest Expense | $63.21MM | $83.34MM | $73.97MM |
| R&D Expense | $3.98MM | $0.00MM | $0.00MM |
| Income(Loss) | $-28.85MM | $75.73MM | $98.57MM |
| Taxes | $-3.85MM | $27.58MM | $29.38MM |
| Profit(Loss)* | $-25.00MM | $48.16MM | $69.19MM |
| Stockholders Equity | $194.84MM | $195.43MM | $228.84MM |
| Inventory | $46.50MM | $32.33MM | $35.56MM |
| Assets | $1,174.13MM | $1,143.31MM | $1,663.59MM |
| Operating Cash Flow | $124.23MM | $274.75MM | $204.98MM |
| Capital expenditure | $1.62MM | $0.46MM | $1.65MM |
| Investing Cash Flow | $-573.69MM | $-70.81MM | $-287.76MM |
| Financing Cash Flow | $436.72MM | $-140.18MM | $-60.60MM |
| Earnings Per Share** | $-0.74 | $1.43 | $2.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.